Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group.
JAMA, 280 (1998), pp. 605-613
[2.]
G.A. Greendale, B.A. Reboussin, P. Hogan, V.M. Barnabei, S. Shumaker, S. Johnson, et al.
Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.
Obstet Gynecol, 92 (1998), pp. 982-988
[3.]
L. Dennerstein, E.C. Dudley, J.L. Hopper, J.R. Guthrie, H.G. Burger.
A prospective population-based study of menopausal symptoms.
Obstet Gynecol, 3 (2000), pp. 351-358
[4.]
Effects of hormonal therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
The Writing Group for the PEPI Trial.
JAMA, 276 (1996), pp. 1389-1396
[5.]
B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, et al.
Reduction of vertebral fracture risk in postmenopusal women with osteoporosis treated with raloxifene.
JAMA, 282 (1999), pp. 637-645
[6.]
Writing group for the Women's Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled trial.
JAMA, 288 (2002), pp. 321-333
[7.]
E. Barrett-Connor, D. Grady, A. Sashegy, P.W. Anderson, D.A. Cox, K.H. Hoszowski, et al.
Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
JAMA, 287 (2002), pp. 847-857
[8.]
A. Blum, W.H. Schenke, L. Hathaway, R. Mincemoyer, M. Kirby, G. Csako, et al.
Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women.
Am J Cardiol, 86 (2000), pp. 892-895
[9.]
A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, et al.
Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
Arteriosclerosis Thromb Vasc Biol, 21 (2001), pp. 1512-1519
[10.]
B.W. Walsh, D.A. Cox, A. Sashegyi, R.A. Dean, R.P. Tracy, P.W. Anderson.
Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.
Am J Cardiol, 88 (2001), pp. 825-828
[11.]
Collaborative Group on Hormonal Factors in Breast Cancer.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer.
Lancet, 350 (1997), pp. 1047-1059
[12.]
P.K. Natrajan, K. Soumakis, R.D. Gambrell Jr..
Estrogen replacement therapy in women with previous breast cancer.
Am J Obstet Gynecol, 181 (1999), pp. 288-295
[13.]
C. Magnusson, J.A. Baron, N. Correia, R. Bergstrom, H.O. Adami, I. Persson.
Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy.
Int J Cancer, 81 (1999), pp. 339-344
[14.]
S.M. Gapstur, M. Morrow, T.A. Sellers.
Hormone replacement therapy and risk of breast cancer with a favourable histology: results of the Iowa Women's Health study.
JAMA, 281 (1999), pp. 2091-2097
[15.]
R.K. Ross, A. Paganini-Hill, P.C. Wan, M.C. Pike.
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
J Natl Cancer Inst, 92 (2000), pp. 328-332
[16.]
C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, R. Hoover.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
JAMA, 283 (2000), pp. 485-491
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición